ArticleClinical oral investigations2022
Titanium platelet-rich fibrin (T-PRF) as high-capacity doxycycline delivery system.
Article in Clinical oral investigations, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 3 syntheses or guidelines pooled it, 29 citations in OpenAlex.
- Antibiotic-Loaded Platelet-Rich Fibrin (AL-PRF) as a New Carrier for Antimicrobials: A Systematic Review of In Vitro Studies.International journal of molecular sciences · 2025Pooled it
- The effect of autologous platelet concentrates as solely grafting material or with bone graft materials in maxillary sinus augmentation: a meta-analysis of randomized controlled trials.Clinical oral investigations · 2025Pooled it
- Periodontal regeneration using platelet-rich fibrin. Furcation defects: A systematic review with meta-analysis.Periodontology 2000 · 2025Pooled it
- Modified minimally invasive surgical technique with clindamycin-augmented or non-augmented platelet-rich fibrin in periodontal regeneration: A randomized clinical trial.Journal of periodontal research · 2025Trial
- Evaluation of leukocyte-platelet rich fibrin as an antibiotic slow-release biological device in the treatment of moderate periodontitis: a randomized controlled clinical trial.BMC oral health · 2024Trial
- A scoping review on platelet-rich fibrin-driven bone regeneration: biological mechanisms and clinical applications in oral and maxillofacial surgery.Journal of the Korean Association of Oral and Maxillofacial Surgeons · 2026Article
- Dose-dependent doxycycline local drug delivery using T-PRF: preliminary in vitro study.Scientific reports · 2026Article
- Evaluation of titanium-prepared platelet-rich fibrin incorporated with amoxiclav, metronidazole, and neem gel on bone regeneration in Wistar rats: a pilot study.Journal of the Korean Association of Oral and Maxillofacial Surgeons · 2026Article
- Evaluating the antimicrobial efficacy, growth factor release drug kinetics of titanium platelet-rich fibrin loaded with amoxiclav, metronidazole and neem gel: anJournal of the Korean Association of Oral and Maxillofacial Surgeons · 2025Article
- Comparative Evaluation of the Effectiveness of Demineralized Freeze-Dried Bone Allografts With Titanium Platelet-Rich Fibrin and Autologous Dentin Graft With Titanium Platelet-Rich Fibrin for Alveolar Socket Preservation: Protocol for a Randomized Controlled Trial.JMIR research protocols · 2025Article
- [Current situation and exploration of clinical transformation of plasmatrix in oral implantology].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2025Review
- Application of Platelet-Rich Fibrin and Concentrated Growth Factors as Carriers for Antifungal Drugs-In Vitro Study.Journal of clinical medicine · 2025Article
- The in vitro antibacterial efficacy of advanced platelet-rich fibrin plus supplemented with metronidazole against Fusobacterium nucleatum.Clinical oral investigations · 2025Article
- Comparative Evaluation of Platelet-Rich Fibrin (PRF) and Concentrated Growth Factor (CGF) as Carriers for Antibiotics-In Vitro Study.International journal of molecular sciences · 2025Article
- How to explain the beneficial effects of leukocyte- and platelet-rich fibrin.Periodontology 2000 · 2025Review
- Letter to the Editor, "Platelet-Rich Fibrin as a Novel Bio-Carrier for the Transfer of Antibiotics to the Root Canal System".Frontiers in dentistry · 2025Article
- The Role of Autologous Platelet Concentrates as a Local Antibiotic Delivery System: A Systematic Scoping Review.Antibiotics (Basel, Switzerland) · 2024Article
- Platelet-rich fibrin as an autologous biomaterial for bone regeneration: mechanisms, applications, optimization.Frontiers in bioengineering and biotechnology · 2024Review
- Can platelet-rich fibrin act as a natural carrier for antibiotics delivery? A proof-of-concept study for oral surgical procedures.BMC oral health · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTitanium platelet-rich fibrin (T-PRF), a second-generation autogenous blood concentrate with tough and thick fibrin meshwork activated by a titanium tube, was used as a drug carrier for doxycycline (Doxy) by injection. The objective of this study is to evaluate the loading capacity of T-PRF, release kinetics of doxycycline-loaded T-PRF, and its antibacterial effects against S. aureus and P. aeruginosa. MATERIALS AND
methodsThe T-PRF and collagen were loaded with Doxy as T-PRF/Doxy and Collagen/Doxy, and their release and antibacterial activities against S. aureus and P. aeruginosa were investigated. Chemical characterization and morphological analysis were performed.
resultsIn comparison with collagen, approximately sevenfold more Doxy, 281 mg/g, was loaded into T-PRF. It was found that 25% of the loaded Doxy was released from T-PRF compared to only 12% from collagen within 72 h. The largest inhibition zone diameter (IZD) was observed for T-PRF/Dox with 32 ± 6 mm and 37 ± 5 mm for P. aereginosa and S. aureus, respectively. However, only 10 ± 5 mm and 10 ± 6 mm IZD were observed for bare T-PRF, and no inhibition zone was observed for the Collagen/Doxy group. A dense fibrin structure was visualized on SEM images of the T-PRF/Doxy group compared to the T-PRF group.
conclusionsT-PRF has higher Doxy loading capacity and long-acting antibacterial effects compared to collagen. T-PRF was shown to have potential autogenous long-term drug-carrying capability for doxycycline. Also, the potential fibrinophilic properties of Doxy were observed to strengthen the structure of T-PRF. CLINICAL RELEVANCE: T-PRF is an autogenous drug career with high loading capacity and extended antibacterial effects for doxycycline. Doxycycline molecules can be visible on T-PRF fibers. This study suggests that T-PRF/Dox could be used as a proper antibiotic delivery device in the treatments of periodontitis and peri-implantitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.